WebBIOVECTRA is equipped to work with a range of biosafety level one (BSL-1) expression systems, including E. Coli and Pichia Pastoris. The types of drug substances we are manufacturing comprise of proteins, enzyme, antibody fragments, and peptides. Scope and Scale 8,000+ m² facility 100 L and 1,000 L single-use fermenters Two 17,000 L fermenters Web16 de set. de 2024 · UK-based biopharmaceuticals producer Mallinckrodt has agreed to sell is CDMO subsidiary BioVectra to HIG Capital, a private equity firm. The price includes a an upfront payment of $135 million, a long-term note for $40 million and contingent payments of up to $75 million, depending on the BioVectra’s future growth.
Mallinckrodt Agrees to Sell BioVectra Inc. to H.I.G. Capital …
Web10 de set. de 2024 · H.I.G. Capital’s acquisition is expected to open doors for BioVectra to continue its contract development and manufacturing growth path. Since 2015, BioVectra has averaged nearly $25 million in annual investments to grow its bioscience capabilities, its team and its technologies. WebHá 2 dias · H.I.G. Capital - Global Alternative Assets Investment Firm Power of the Platform *Based on total capital commitments managed by H.I.G. Capital and affiliates. … orchard park apartments ellicott city md
H.I.G. Capital - Global Alternative Assets Investment Firm
Web4 de nov. de 2024 · MIAMI – November 4, 2024 – H.I.G. Capital (“H.I.G.”), a leading global private equity investment firm with over $34 billion of equity capital under management, … WebH.I.G. Capital 79,740 followers on LinkedIn. A leading global private equity investment firm with $55 billion of equity capital under management. H.I.G. Capital is a leading global … Web18 de nov. de 2024 · BIOVECTRA is a global biotech and pharmaceutical CDMO (contract development and manufacturing organization) that specializes in clinical-to-commercial … ipswich school archive